2 completed, 1 active not recruiting, 1 recruiting, 1 withdrawn. 2 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 2 | Completed 1, Withdrawn 1 |
| Phase 2 | 2 | Completed 2 |
Follow Multiple Endocrine Neoplasia Type 2b: new trials by email Literature Review of Multiple Endocrine Neoplasia Type 2b trials Research Report on Multiple Endocrine Neoplasia Type 2b
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Early Check: Expanded Screening in Newborns Confirmatory Testing - Spinal Muscular Atrophy, Fragile X Syndrome | Active not recruiting | RTI International | 30000 | 2018-10-15 | 2026-07-01 | |
| Veliparib, Capecitabine, and Temozolomide in Patients With Advanced, Metastatic, and Recurrent Neuroendocrine Tumor Capecitabine, Temozolomide, Veliparib - Functional Pancreatic Neuroendocrine Tumor, Malignant Somatostatinoma | Phase 1 | Withdrawn | Vanderbilt-Ingram Cancer Center | 2017-12-01 | 2017-09-28 | |
| Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Rare Disorders, Undiagnosed Disorders | Recruiting | Sanford Health | 20000 | 2010-07-01 | 2025-05-29 | |
| Vandetanib to Treat Children and Adolescents With Medullary Thyroid Cancer Vandetanib - Medullary Thyroid Carcinoma, Multiple Endocrine Neoplasia Type 2A | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 17 | 2007-07-20 | 2020-12-22 |
| Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer Sorafenib Tosylate - Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 21 | 2006-11-03 | 2024-02-06 |
Multiple Endocrine Neoplasia Type 2a (4) · Carcinoma, Medullary (3) · Ataxia with vitamin E deficiency (2) · Cystinosis (2) · Hyperargininemia (2) · Hypophosphatasia (2) · Leukodystrophy, Metachromatic (2) · Multiple Endocrine Neoplasia (2) · Multiple Endocrine Neoplasia Type 1 (2) · Pitt-Hopkins syndrome (2) · Stickler syndrome, type 1 (2) · Stickler syndrome, type 2 (2) · 3-Hydroxy-3-Methylglutaryl-CoA Lyase Deficiency (1) · 3-Hydroxyacyl-CoA Dehydrogenase Deficiency (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (5) · Endocrine Gland Neoplasms (5) · Endocrine System Diseases (5) · Genetic Diseases, Inborn (5) · Neoplasms (5) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Neoplasms, Multiple Primary (5) · Neoplastic Syndromes, Hereditary (5) · Neoplasms, Germ Cell and Embryonal (4) · Neoplasms, Glandular and Epithelial (4) · Neoplasms, Nerve Tissue (4) · Neuroectodermal Tumors (4) · Adenocarcinoma (3) · Carcinoma (3)
Capecitabine (1) · Sorafenib (1) · Temozolomide (1) · vandetanib (1) · veliparib (1)
National Cancer Institute (NCI) (2) · RTI International (1) · Sanford Health (1) · Vanderbilt-Ingram Cancer Center (1)
United States (4) · Australia (1)
Bhavana Konda (1) · Brigitte C Widemann, M.D. (1) · Curt Scharfe, MD, PhD (1) · Jordan Berlin, M.D. (1)
PMID 23766359, PMID 24617713, PMID 25972901, PMID 29187393, PMID 31315600, PMID 35142618
N01CM00070 (1), N01CM62207 (1), P30CA016058 (1)